Volpara Receives FDA Clearance for Breast Density Algorithm
Software improves on breast density assessment algorithm with artificial intelligence.
Volpara Health announced Friday it has received 510(k) clearance from the U.S. Food & Drug Administration for the latest version of Volpara Imaging Software.
This version – VIS 3.2 – incorporates learnings from artificial intelligence to augment the robustness of the breast density assessment algorithm. In addition, this clearance approves VIS 3.2 for use on other mammography machines, including those from Giotto and Siemens.
The new version offers improved imaging processing security through the Open Virtual Appliance architecture, and it also makes it easier for Volpara to monitor, services, and update software, company officials said.
“These new innovations improve the overall security, scalability, robustness, and breadth of our breast health offering,” said Ralph Highnam, Ph.D., Volpara’s Group chief executive officer. “Our objective with each enhancement is the pursuit of our mission – to eliminate advanced-stage breast cancer and save more families from cancer.”
With this approval, Volpara marks its fifth clearance since launching Volpara Imaging Software in 2010. It is a key science algorithm that supports the Volpara Breast Health Platform, a product suite designed to improve early breast cancer detection through augmented mammography quality and workflow, volumetric breast density assessment, and personalized breast care.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
What a New Study Reveals About Adjunctive DBT and Early-Stage Invasive Breast Cancer
December 6th 2023The combination of digital breast tomosynthesis (DBT) and digital mammography had a 21.6 higher invasive breast cancer detection rate for stage 1 tumors than digital mammography alone, according to a new study involving nearly 100,000 women.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
